| 0.012 0 (0%) | 10-24 14:10 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.05 | 1-year : | 0.09 |
| Resists | First : | 0.04 | Second : | 0.07 |
| Pivot price | 0.01  |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0.01 |
MA(20) : | 0.01 |
| MA(100) : | 0.05 |
MA(250) : | 0.18 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 13.9 |
D(3) : | 13.5 |
| RSI | RSI(14): 47.4 | |||
| 52-week | High : | 1.13 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TTOO ] has closed above bottom band by 38.0%. Bollinger Bands are 11.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.01 - 0.01 | 0.01 - 0.01 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Wed, 04 Jun 2025
T2 BIOSYSTEMS Earnings Preview: Recent $TTOO Insider Trading, Hedge Fund Activity, and More - Nasdaq
Thu, 20 Feb 2025
T2 Biosystems initiates major layoffs, seeks asset sale - Investing.com
Tue, 18 Feb 2025
Medical diagnostics firm T2 Biosystems cuts ‘substantially all’ workers - The Business Journals
Fri, 14 Feb 2025
T2 Biosystems Reduces Workforce Amid Nasdaq Delisting Notice - TipRanks
Tue, 11 Feb 2025
T2 Biosystems to be delisted from Nasdaq - Investing.com
Tue, 07 Jan 2025
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 28 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 8 (%) |
| Held by Institutions | 38 (%) |
| Shares Short | 846 (K) |
| Shares Short P.Month | 942 (K) |
| EPS | -0.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.63 |
| Profit Margin | 0 % |
| Operating Margin | -511.9 % |
| Return on Assets (ttm) | -84.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 34.9 % |
| Gross Profit (p.s.) | -0.68 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -1.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -37 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.41 |
| PEG Ratio | 0 |
| Price to Book value | -0.02 |
| Price to Sales | 0.04 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|